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Abstract 
 
Objective: To determine whether the decrease in pancreatic triacylglycerol during 
weight loss in type 2 diabetes is simply reflective of whole body fat, or specific to 
diabetes and associated with the simultaneous recovery of insulin secretory function.  
Research Design and Methods: Individuals listed for gastric bypass surgery who had 
either type 2 diabetes or normal glucose tolerance matched for age, weight and gender 
were studied before and 8 weeks after surgery. Pancreas and liver triacylglycerol were 
quantified using in-phase, out-of-phase magnetic resonance imaging. First phase 
insulin response to a stepped intravenous glucose infusion, hepatic insulin sensitivity 
and glycemic and incretin responses to a semi-solid test meal were also measured.  
Results: Weight loss after surgery was similar (NGT: 12.8±0.8% and T2DM: 
13.6±0.7%) as was change in fat mass (56.7±3.3 to 45.4±2.3 vs. 56.6±2.4 to 
43.0±2.4kg). Pancreatic triacylglycerol did not change in NGT (5.1±0.2 to 5.5±0.4%) 
but decreased in the T2DM group (6.6±0.5 to 5.4±0.4%; p=0.007). First phase insulin 
response to a stepped intravenous glucose infusion did not change in NGT (0.24 
(0.13-0.46) to 0.23 (0.19-0.37) nmol min-1 m-2) but normalised in T2DM (0.08 (-0.01-
0.10) to 0.22 (0.07-0.30) nmol min-1 m-2 at week 8 (p=0.005). No differential effect of 
incretin secretion was observed post-gastric bypass, with more rapid glucose 
absorption bringing about equivalently enhanced GLP-1 secretion in the two groups.  
Conclusions: The fall in intra-pancreatic triacylglycerol in type 2 diabetes which 
occurs during weight loss is associated with the condition itself rather than decreased 
total body fat.  
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Type 2 diabetes (T2DM) has reached epidemic proportions, affecting 9.2% of the US 
population and costing the country $322 billion in 2012 [1]. The condition is widely 
recognised to be caused by a combination of insulin resistance and insulin secretory 
failure. However, insulin resistance alone does not cause blood glucose to rise [2] and 
type 2 diabetes occurs only when the acute insulin response of pancreatic beta cells 
becomes inadequate to control blood glucose [3; 4]. The etiologic process underlying 
this is still uncertain. Inhibition by excess intracellular fatty acids or their metabolites 
is a potential mechanism [5-7]. We have previously demonstrated in people with 
T2DM that weight loss over 8 weeks can normalize both the acute insulin response 
and intrapancreatic triacylglycerol concentration [8]. The resulting normoglycemia 
persists providing that weight regain is avoided [9]. These observations have 
confirmed some aspects of the twin cycle hypothesis of etiology of T2DM [10]. 
It remains uncertain whether the change in intra-pancreatic triacylglycerol is specific 
to the diabetes itself or whether it simply reflects decrease in whole body fat content 
and would occur during any substantial weight loss.  Comparison of changes in 
T2DM and normal glucose tolerance (NGT) during weight loss could define those 
changes specific to the recovery of insulin secretory capacity. Achieving equivalent 
dietary weight loss in NGT individuals who do not have the motivation of potentially 
reversing their diabetes to normal would be challenging. Gastric bypass surgery for 
obesity produces reliable weight loss and permits detailed comparison of the 
pathophysiologic changes in T2DM and NGT groups. 
Major changes in incretin hormones occur after RYGB which could potentially 
contribute to the observed increase in meal related insulin secretion [11]. Given the 
subnormal glucagon-like peptide 1 (GLP-1) response to food ingestion in T2DM [12], 
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RYGB may exerts a specific effect in T2DM which differs from that in non-diabetic 
subjects. Some studies have supported this concept [13] although similar restoration 
of normoglycemia has been observed after calorie restriction alone [14]. Few studies 
have compared the effect of gastric bypass in T2DM and NGT both on physiologic 
incretin function and incretin-independent, intravenous glucose mediated insulin 
secretion. 
The aims of this study were to test the hypotheses that the restoration of first phase 
insulin secretion after Roux-en-Y gastric bypass surgery (RYGB) would be 
accompanied by decrease in pancreatic triacylglycerol specifically in T2DM, and that 
the post-surgery change in incretin hormone responses would not differ in T2DM and 
NGT. As change in pancreas triacylglycerol must reflect export of very low density 
lipoprotein (VLDL) triacylglycerol from the liver, hepatic triacylglycerol content and 
hepatic insulin sensitivity were also assessed. 
 
Research Design and Methods 
Participants 
Individuals listed for laparoscopic RYGB were identified from two regional bariatric surgery 
centres. Individuals with T2DM (n=18) were recruited with diabetes duration<15 yr, aged 25-
65 yr, BMI up to 45 kg/m2 (due to scanner constraints), HbA1c<10% (86 mmol/mol) and no 
significant renal or hepatic dysfunction (creatinine<150 µmol/l; alanine aminotransferase 
(ALT) <2.5-fold above upper limit of normal). Exclusion criteria were: contraindication to 
magnetic resonance (MR) scanning; alcohol consumption >14 units/wk; previous bowel 
surgery; or treatment with steroids, thiazolidinediones or GLP-1 analogues. The T2DM 
(n=18) and NGT individuals (n=9) were group matched for age and weight (49.1±1.6 vs. 
46.3±2.1yr, 121.0±3.0 vs. 114.5±5.0 kg, 11F:7M, 7F:2M respectively) and NGT confirmed 
by 75g oral glucose tolerance test. Impaired glucose tolerance was found in 2 subjects and 
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screening was continued until the planned group size of 9 NGT was achieved. In the T2DM 
group, there were 3 individuals on insulin and 9 individuals on SU at recruitment.  
The study protocol was approved by the Newcastle upon Tyne 1 Research Ethics Committee. 
All participants provided written informed consent.  
One individual did not undergo surgery following baseline studies due to the diagnosis of an 
unrelated medical problem. 
 
Experimental Protocol 
The T2DM and NGT participants were studied just before surgery and at 8 weeks 
post-operatively. Pre-operatively all participants were asked to follow a hypocaloric 
(approximately 1200kcal) diet for 7-10 days. At each time point, metabolic and 
incretin responses to a standard meal test, first phase and maximal insulin secretion 
and pancreas and liver triacylglycerol content by MR scanning were measured. 
Participants were asked to stop metformin and/or sulfonylureas at least 72 hours prior 
to the first study, or to stop insulin at least 24 hours prior and all remained off 
hypoglycemic agents thereafter. Intensive physical activity/alcohol/caffeine intake 
were avoided 48 hours prior to each study.  
All metabolic studies were performed after a 10h overnight fast.  
 
Surgery 
RYGB was performed laparoscopically in all patients. A biliopancreatic limb of 50-
70cms from the duodenojejunal flexure was anastomosed to the 30-50ml gastric 
pouch. An alimentary limb of 100-150 cms was then measured and a side to side 
antimesenteric jejuno-jejunostomy carried out. At the time of operation, 2 patients 
with type 2 diabetes underwent sleeve gastrectomy instead of RYGB due to the 
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presence of significant intra-abdominal adhesions. These 2 patients have been 
excluded from the incretin analyses.  
 
Body composition and anthropometry 
Body composition was determined using a Bodystat1500 (Bodystat Ltd, Isle of Man, 
UK). Waist and hip circumferences were measured using a standard non-distensible 
tape measure and height by stadiometer by one observer (SS).  
 
Meal test 
Each test was performed with the participant semi-reclined at a 45 angle in bed to 
avoid positional change affecting gastric emptying. Baseline blood samples were 
taken at -10 and 0 min. Subjects were then asked to consume a semi-solid meal within 
3 minutes (10g Mornflake Instant Porridge Oats, 64g whole milk and 6g acacia honey: 
100 kcal; 57% carbohydrate; 28% fat; 13% protein), designed in accordance with the 
expected volume and consistency of diet consumed one week following RYGB. 
Samples for glucagon, GLP-1 and gastrointestinal peptide (GIP) were taken into 
chilled EDTA tubes containing trasylol. All samples were immediately centrifuged at 
4C and the plasma separated into aliquots and frozen at -40C until analysis. 
Samples were taken every 10 min for the first 30 min of the test, then every 30 min 
until 2 hours. 
 
Measurement of intra-organ triacylglycerol content 
Magnetic resonance (MR) data were acquired using a 3 Tesla Philips Achieva scanner 
(Philips, Best, The Netherlands) with either a 6 channel cardiac array (Philips), or four 
large surface coils  (large and medium flex coils, Philips) if required due to body 
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habitus. Data were acquired using a three point Dixon method [15] with gradient-echo 
scans acquired during four 17 second breath holds (repetition time (TR)/echo time 
/averages/flip angle = 50ms/3.45, 4.60, 5.75ms/1/5°. Critically, participant 
cooperation was maximised by careful explanation from research radiographers. A 
matrix size of 160×109 and with a field view of 400-480 mm was used according to 
volunteer size. The liver data were acquired with slice thickness 10mm and the 
pancreas data with slice thickness 5mm.  The triacylglycerol and water contributions 
of the MRI signal were separated by mathematical modelling of their known chemical 
shifts using an in-house programme written in MATLAB, with the triacylglycerol 
content in the images expressed as a percentage of the total signal in each pixel. The 
intraorgan triacylglycerol percentage was evaluated from regions of interest on two 
image slices of pancreas and five image slices of liver, defined and averaged by one 
observer (SS). As the analysis is image-based, selection of regions of interest ensures 
no inclusion of visceral adipose tissue and the measurement is specifically taken from 
the parenchyma of the pancreas avoiding any incursion of adipose tissue. The 
pancreas triacylglycerol analysis was carried out blinded to subject status and 
timepoint. 
 
Hepatic glucose production and insulin sensitivity 
 [6′6′-2H] glucose (98% enriched; Cambridge Isotope Laboratories, MA, USA) was 
used to determine hepatic glucose production [16]. Basal rates were calculated during 
the last 30 min of the 150 min basal period. The hepatic insulin resistance index was 
derived from the product of fasting plasma insulin and fasting hepatic glucose 
production [17]. An isoglycemic–hyperinsulinemic clamp (insulin infusion rate 40 
mU m2 min1) was initiated at 0 min. Each participant was clamped at the glucose level 
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observed at the end of the basal period. Isoglycemia was used to ensure that the true 
metabolic condition of each participant could be observed at each study time point. 
Whole-body insulin sensitivity was determined during the last 30 min of the 120 min 
hyperinsulinemic glucose clamp as whole-body glucose disposal per kg of fat free 
mass corrected for glucose space and urinary loss [18]. In order to correct for the 
difference in fasting glucose levels during the course of the study, whole body insulin 
sensitivity was expressed as glucose metabolic clearance by dividing the whole-body 
glucose disposal rate by steady-state plasma glucose. 
 
Stepped insulin secretion test with arginine (SISTA) 
Sixty minutes after the clamp test, when glucose levels had stabilised at fasting levels, 
two consecutive 30 min square-wave steps of hyperglycemia (2.8 and 5.6 mmol/l 
above baseline) were achieved by priming glucose doses followed by variable 20% 
glucose infusion [19]. Blood samples for determination of plasma glucose, insulin and 
C-peptide concentrations were obtained every 2 min for the first 10 min then every 5 
min for each step. An arginine bolus was administered during the second step of 
hyperglycemia, followed by sampling every 2 min for 10 min. Insulin secretion rate 
was calculated using a computerised program implementing a regularisation method 
of deconvolution  and using a population model of C-peptide kinetics as previously 
described [8]. 
 
Analytical procedures 
Plasma glucose was measured by the glucose oxidase method (YSI glucose analyser, 
Yellow Springs, OH). Serum insulin was measured using ELISA kits (DAKO; Ely, 
Cambridge, UK). Serum C-peptide was measured using ELISA kits (DAKO; Ely, 
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Cambridge, UK or Mercodia; Uppsala, Sweden with correction factor to ensure 
comparability). Plasma NEFA concentration was measured using a FLUOstar Omega 
microplate reader (BMG labtech; Ortenberg, Germany) by a commercially available 
enzymatic calorimetric kit (NEFA HR Reagent 1 and 2; Alpha laboratories, Eastleigh, 
Hampshire, UK).  β- Hydroxybutyrate levels were measured to confirm dietary 
compliance using the Optium Exceed ketone meter (Abbott Diabetes Care, 
Oxfordshire, UK). [6′6′-2H] glucose was measured using Gas Chromatography Mass 
Spectrometry (GC/MS) technique on a Thermo ‘Voyager’ single quadruple mass 
spectrometer connected to a Thermo Finnigan Trace 2000 gas chromatograph 
(Thermo Scientific, Waltham, MA, USA). HbA1c, LFTs, gamma glutamyl transferase 
(GGT), and lipids were measured at a Clinical Pathology Accredited laboratory 
(Newcastle upon Tyne Hospital NHS Foundation Trust, Department of Clinical 
Biochemistry). Human Total GLP-1 (7-36, 9-36) was measured using ELISA kits 
(Alpco Diagnositics; Salem, NH, USA). Human Total GIP was measured using 
ELISA kits (Merck Millipore, Watford, UK). PNPLA3 genotyping was performed on 
DNA extracted from white blood cells. 10 ml of whole blood was collected in EDTA 
and after thorough mixing was then stored at -40C. DNA was isolated and 
genotyping performed (blinded to the clinical parameters) using TaqMan SNP 
Genotyping Analysis (Applied Biosystems, USA) as described previously [20]. 
 
Statistical Analysis 
Data are presented as mean ± SEM for parametric and median (range) for non-
parametric data. Insulin secretion rates are given as median with 25th and 75th 
percentile. Statistical analysis used Student’s paired and unpaired t-test, Mann 
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Whitney U, Wilcoxon Rank and Spearman Rank as appropriate using Minitab 16 
statistical program (www.minitab.com). 
 
 
Results 
 
Weight loss 
Pre-operative weight did not differ between the T2DM and NGT groups (121.1±3.0 
vs. 114.5±5.0 kg; p=0.244). At 8 post-operative weeks weight loss was similar in the 
two groups (13.6±0.7 % and 12.8±0.8 % respectively; p=0.286) as was change in total 
body fat content (Table 1). 
 
Plasma glucose, insulin and metabolites 
Fasting plasma glucose decreased from 9.4±0.8 pre-surgery to 6.4±0.4 mmol/l at 
week 8 in the T2DM group (p<0.001) and from 5.2±0.2 to 4.9±0.1 mmol/l  in the 
NGT group (p=0.196). HbA1c decreased from 7.6±0.4 to 6.2±0.2 % (59±4 to 
44±2mmol/mol) in the T2DM group (p<0.001) compared to 5.4±0.1 to 5.2±0.1 % 
(36±1 to 33±1mmol/mol) in the NGT group (p=0.01). 
Fasting insulin levels fell in both groups (T2DM: 15.3 (4.3-61.2) to 11.3 (2.9-27.0) 
mU/l (p<0.001); NGT: 10.7±1.4 to 6.7±0.7 mU/l (p<0.01). There were significant 
decreases in fasting triacylglycerol, ALT and GGT in the T2DM but not the NGT 
group (Table 1). Fasting beta-hydroxybutyrate increased from 0.20 (0.00-0.70) to 0.30 
(0.10-1.00) in the T2DM group (p=0.011) and from 0.33±0.08 to 0.55±0.15 in NGT 
(p=0.07). There was no difference in change from pre-surgery to week 8 in beta-
hydroxybutyrate between the 2 groups ( -0.2 (-0.6-0.5) NGT -0.1 (-1-0); p=0.98).  
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Pancreas triacylglycerol content 
Pancreatic triacylglycerol content was higher pre-surgery in the T2DM group 
compared to the NGT group (6.6±0.5 vs. 5.1±0.2 %; p=0.009). By week 8, pancreatic 
triacylglycerol content had decreased in the T2DM group to levels similar to the NGT 
group (6.6±0.5 to 5.4±0.4 %; p=0.007) but with no change in the NGT group (5.1±0.2 
to 5.5±0.4 %; p=0.437) (Figure 1B) despite comparable decrease in whole body fat 
mass (Table 1). 
 
Change in insulin secretion 
Pre-surgery, the first phase insulin response (baseline to 6 min insulin secretion rate) 
in T2DM was severely impaired compared to the NGT group (0.08 (-0.01-0.10) vs. 
0.24 (0.13-0.46); p=0.011; Figures 1A & 2B). There was marked restoration of the 
first phase insulin response in T2DM post-surgery: increasing to 0.22 (0.07-0.30) 
nmol min-1 m-2  at week 8 in the T2DM group (p=0.005; Figures 1A & 2C). There was 
no change in first phase insulin response in the NGT group: 0.24 (0.13-0.46) at 
baseline and 0.23 (0.19-0.37) nmol min-1 m-2 at week 8 (p=0.464; Figures 1A, 2B & 
2C). Arginine-induced insulin response in the T2DM group was 0.80 (0.70-0.90) at 
baseline and 0.71 (0.50-1.15) at week 8 (p=0.567), and in the NGT group was 0.85 
(0.71-1.21) at baseline and 0.62 (0.55-1.28) at week 8 (p=0.896). 
 
Hepatic triacylglycerol content and liver enzymes 
Pre-surgery, hepatic triacylglycerol content was over 2-fold higher in the T2DM 
group compared to the NGT group (9.3±1.5 vs. 4.2±1.4 %; p=0.022; Supplemental 
Figure 1A). Post-surgery, it decreased to a greater extent in the T2DM group (T2DM: 
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9.3±1.5 to 5.2±0.8 % (p=0.018); NGT: 4.2±1.4 to 2.3±0.6 % (p=0.059). These 
changes were reflected in the fall in serum ALT and GGT following surgery in the 
T2DM group only (Table 1). 
 
Hepatic insulin sensitivity 
Basal hepatic glucose production in T2DM decreased post-surgery (3.60±0.24 to 
2.69±0.12 mg/kgffm/min; p<0.001; Supplemental Figure 1B). There was no significant 
change in the NGT group (2.60±0.08 to 2.51±0.20 mg/kgffm/min; p=0.555). Hepatic 
insulin sensitivity improved in the T2DM group: hepatic IR index 2.76±0.41 to 
1.33±0.23 mmol.min-1.kgffm
-1.pmol.l-1 (p=0.002); NGT group: 1.18±0.19 to 0.70±0.07 
mmol.min-1.kgffm
-1.pmol.l-1 (p=0.062)(Supplemental Figure 1C). The insulin induced 
suppression of hepatic glucose production was greater in the T2DM group at 8 weeks 
post-RYGB: 67±4 to 85±3 %; p<0.001, with no change in the NGT group: 84±4 to 
77±8 %; p=0.339. 
 
Peripheral tissue insulin sensitivity 
Insulin stimulated glucose metabolic clearance did not change in either group: 2.46 
(0.86-8.80) to 2.69 (0.45-10.07) ml/kgffm/min in T2DM (p=0.223) and 4.51±0.63 to 
4.79±0.70 ml/kgffm/min in NGT (p=0.572). Both before surgery (p=0.033) and after 
surgery (p=0.024) peripheral insulin sensitivity was significantly lower in the T2DM 
group. 
 
Subcutaneous and visceral fat data  
 
Pre-surgery, there was no difference between subcutaneous adipose tissue (SAT) area 
in T2DM compared to NGT (453.8±28.9 cm2 vs. 496.4±16.0 cm2 ; p=0.318). Visceral 
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adipose tissue (VAT) area was 300.4±17.5 cm2 in T2DM compared to 244.5±28.4 
cm2 in NGT (p=0.09). In T2DM, SAT decreased to 393.2±26.8 cm2 at week 8 
(p<0.001) and VAT to 241.3±11.0 cm2 (p<0.001). In NGT, SAT decreased to 
409.7±26.0 cm2 (p=0.016) and VAT decreased to 187.9±28.3 cm2 (p=0.01).  
 
Change in meal tolerance test 
As a result of the gastroenterostomy, the rise in plasma glucose over the first 20 min 
of the meal test was greater in both the T2DM and NGT groups (0.6±0.1 pre-
operatively to 1.8±0.1 mmol/l post-operatively (p<0.001) and 0.5±0.1 to 1.7±0.2 
mmol/l (p=0.004) respectively) (Figure 3A). There was a significant difference in 
decrease of peak glucose between T2DM and NGT (1.84 (-1.06-11.5) vs. -0.66 (-
1.73-0.34); p<0.001). 2 hour post-meal glucose was lower in both groups: 9.4±0.8 to 
6.4±0.3 mmol/l in the T2DM group (p<0.001) and 5.5±0.2 to 5.0±0.0mmol/l in the 
NGT group (p=0.022). The change in 2 hour post-meal glucose between T2DM and 
NGT was also significant: (1.87 (-0.02-11.49) vs. 0.41 (-0.26-0.91); p<0.001).  
 
The incremental rise in plasma insulin over the first 20 minutes increased in both 
groups at 8 weeks post-RYGB, with a higher and earlier peak plasma insulin being 
achieved (T2DM pre-operatively: 35.2±4.9 mU/l at 60 (10-120) min vs. week 8: 
47.7±5.8 mU/l at 20 (10-30) min; p=0.01; NGT pre-operatively: peak insulin 37.0±5.0 
mU/l at 60 (30-120) min vs. week 8: 58.1±10.0 mU/l at 20 (20-30) min; p=0.032) 
(Figure 3B). 
 
Peak GLP-1 levels during the meal test increased from 5.0±0.3 to 12.7±1.3 pmol/l in 
the T2DM group (p<0.001) and 5.1±0.6 to 12.9±1.2 pmol/l in the NGT group 
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(p=0.001) (Figure 3C). Peak GIP levels increased from 197.6±18.1 to 246.2±24.4 
pg/ml in the T2DM group (p=0.051) but did not change in the NGT group: 
206.7±28.6 to 231.2±32.6 pg/ml (p=0.482). There was an earlier rise in GIP in both 
groups (Figure 3D). 
 
PNPLA3 
In the whole group (n=26), the rs738409 C to G adiponutrin/PNPLA3 genotype 
(coding for I148M) was found in 9 individuals: 8 were heterozygous for the SNP: CG 
(148I/M) and 1 homozygous: GG (148M/M), 6 of whom had T2DM and 3 of whom 
were NGT. In the T2DM group, mean baseline liver triacylglycerol content was 
8.7±1.9 vs 10.6±2.3 % (p=0.59) in those with CC vs. CG/GG. At 8 weeks post-
operatively this was 3.9±0.5 and 8.2±1.9 % respectively (p=0.006). The GG 
homozygous T2DM individual had liver triacylglycerol of 4.1% pre-operatively and 
6.1% postoperatively. 
 
Conclusions 
 
Despite similar weight loss following bariatric surgery in groups of well-matched 
individuals with T2DM or NGT, intra-pancreatic triacylglycerol decreased uniquely 
in T2DM. This was associated with normalisation of first phase insulin secretion in 
the T2DM group.  There was no change in intra-pancreatic triacylglycerol in the NGT 
group despite a 5 unit decrease in BMI. Hepatic insulin sensitivity both fasting and 
during insulin stimulation normalised in the T2DM group in step with a greater 
decrease in liver triacylglycerol compared to the NGT group. The meal-related rise in 
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plasma glucose was faster in both groups after RYGB and there was an equivalently 
enhanced GLP-1 response. 
 
T2DM develops as a consequence of positive calorie balance over many years and 
ectopic fat storage appears to be central to the process [10]. The importance of 
pancreas triacylglycerol in the pathogenesis of T2DM was initially suggested by a 
study in obese rodents [21]. In humans with T2DM supranormal pancreas 
triacylglycerol content decreases as weight loss allows recovery of first phase insulin 
secretion [22]. Identification of the location of triacylglycerol within the pancreas has 
been hampered by rapid post-mortem autolysis, but study of pancreata retrieved and 
not used for pancreas transplantation has shown intracellular fat droplets widely 
distributed within the exocrine cells, in addition to widely scattered isolated 
adipocytes [23].. Exposure to even modest concentrations of fatty acids causes 
marked triacylglycerol accumulation in human islets in vitro [7]. It is likely that local 
lipolysis is likely to bring about interstitial and intracellular concentrations of fatty 
acids sufficient to inhibit beta cell function. Fatty acid receptors are expressed in 
mouse and human pancreatic beta cells and when knocked out allow recovery of 
insulin secretion [24]. However, the change in pancreas triacylglycerol content 
demonstrated during reversal of  T2DM is small in absolute terms (~1% of the 
pancreas volume) and consistent with change in intracellular triacylglycerol content. 
Cross sectional studies are relatively insensitive and there are ethnic differences in 
intrapancreatic triacylglycerol [25; 26]. Decreased insulin secretion after oral glucose 
has been observed to reflect increased pancreas triacylglycerol in non-diabetic 
individuals [22].  
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The method used to quantify intra-pancreatic triacylglycerol must be considered. MR 
spectroscopy gathers chemical information from a pre-defined volume, and with 
careful application physiologically relevant data can be acquired [26]. If the volume 
selected is too large it is likely that visceral fat will be included in the measurement 
[27]. Use of the 3-point Dixon imaging method avoids this problem as chemical 
information is derived post-acquisition and placement of the volume of interest is 
guided by the image [8]. However, care is required in ensuring validity of the method 
as otherwise serious errors including negative numbers for percentage tissue 
triacylglycerol may be derived [27]. In the present study we have used a reproducible, 
robust method with blinded analysis.  At 8 weeks post-surgery there was a 15% 
decrease in pancreas triacylglycerol levels in T2DM to the same level as NGT 
individuals, demonstrating that the increase in the fat content of the pancreas is 
specific to the condition rather than being a reflection of obesity per se. This weight 
loss associated decrease in pancreas triacylglycerol content occurred at the same time 
as the recovery in first phase insulin secretion, as previously observed following a 
very low calorie diet [8]. 
Fasting plasma glucose concentration is determined by the rate of hepatic glucose 
production [16] which in turn is controlled by insulin [28]. Hepatic insulin sensitivity 
is known to be impaired by increased liver triacylglycerol [17; 29]. Short term 
carbohydrate overfeeding can induce liver triacylglycerol accumulation [30] and 
furthermore, weight loss with consequent reduction in liver fat is associated with 
improvements in insulin sensitivity and fasting plasma glucose levels [16; 31]. The 
present study demonstrates a greater reduction in liver fat content post-RYGB in 
individuals with T2DM compared to NGT with normalisation of hepatic insulin 
sensitivity. The similarity in change in liver triacylglycerol and hepatic insulin 
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sensitivity in both groups was striking. In NGT, endogenous glucose production falls 
after bariatric surgery when baseline liver triacylglycerol is high [32]. Individual 
differences in susceptibility to the adverse metabolic effects of intra-hepatic fat are 
implied by the range of baseline liver triacylglycerol in the T2DM group. Data from 
the UKPDS on individuals with normal BMI supports the concept of a variable 
personal fat threshold of susceptibility to develop and reverse T2DM [33]. The 
PNPLA3 polymorphism, measured because this is a specific and known factor 
determining intra-hepatic triacylglycerol, blunted the weight-loss associated decrease 
in liver fat. 
 
The markedly increased nutrient-stimulated secretion of GLP-1 after RYGB is well 
recognised, and the present observations confirm this. Normalisation of the first phase 
insulin response to intravenous infusion of glucose demonstrates the improvement to 
be independent of acute incretin stimulation. After RYGB, a 2.6-fold increase of 
insulin secretion assessed by IVGTT disposition index has been reported [34]. VLCD 
or RYGB result in similarly increased insulin secretion in both groups despite a 
marked increase in GLP-1 after RYGB only [35]. A specific GLP-1 receptor 
antagonist does not affect insulin secretion post RYGB [36; 37].  
Nutrients pass rapidly into the mid-jejunum post RYBG [38]. Most studies have used 
an oral glucose challenge [11; 34] or liquid meal [39] with very rapid absorption and a 
non-physiological incretin stimulus [36]. The present study used a semi-solid meal to 
minimise the rapid nutrient entry into the jejunum, but even so a more rapid rise in 
glucose levels was observed after surgery in both T2DM and NGT. The GIP peak 
after test meal was earlier and greater in both groups post-RYGB. Overall, it appears 
18 
 
that acute post-meal enhanced incretin secretion does not explain the improved beta 
cell function in T2DM following bariatric surgery.  
 
The limitations of the study must be discussed. The group sizes were sufficient to 
achieve clear statistical significance, and although smaller numbers of NGT were 
studied the range of responses within this group was small. Although the T2DM 
group were unselected in terms of diabetes duration and treatments, this is 
representative of the heterogeneous population undergoing bariatric surgery. We 
measured total rather than active GLP-1, although the responses of active and total 
GLP-1 are tightly correlated [40]. 
 
In summary, T2DM individuals exhibit an attenuated first phase insulin response and 
increased pancreatic triacylglycerol compared to BMI-matched NGT individuals. 8 
weeks after bariatric surgery both first phase insulin response and pancreas 
triacylglycerol normalised uniquely in the T2DM group. GLP-1 response after a semi-
solid meal improved equally in T2DM and NGT. These observations support the 
concept of intra-pancreatic triacylglycerol and metabolites being central to the 
etiology of T2DM. The understanding of T2DM as a disease of fat accumulation 
above a personal threshold lays the foundation both for more appropriate clinical 
management. 
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 T2DM 
Before 
surgery 
T2DM 
After 
surgery 
p NGT 
 Before 
Surgery 
NGT  
After  
Surgery 
p 
Weight  
(kg) 
121.1±3.0 104.5±2.7 <0.001 114.5±5.0 99.7±4.6 <0.001 
BMI  
(kg/m2) 
42.7±0.7 36.9±0.7 <0.001 41.3±1.0 36.4±0.8 <0.001 
Fat mass 
(kg) 
56.6±2.4 43.0±2.4 <0.001 56.7±3.3 45.4±2.3 <0.001 
Waist:Hip 
ratio 
0.97±0.02 0.94±0.02 0.006 0.90±0.03 * 0.87±0.03 # 0.066 
Fasting 
plasma 
glucose 
(mmol/l) 
9.2±0.8 6.2±0.3 <0.001 5.2±0.1 4.9±0.1 0.089 
2hr plasma 
glucose 
(mmol/l) 
9.4±0.8 6.4±0.3 <0.001 5.4±0.2 * 5.0±0.0 # 0.022 
Fasting 
serum 
insulin 
(mU/l) 
15.3 
 (4.3-61.2) 
11.3  
(2.9-27,0) 
<0.001 11.0±1.6 6.7±0.7 # 0.008 
2hr serum 
insulin 
(mU/l) 
18.4 
 (5.2-78.9) 
11.2 
 (4.9-31.0) 
0.001 12.4 * 
(4.4-63.5) 
6.0 # 
(5.0-7.4) 
0.042 
 
Fasting 
glucagon 
(ng/l) 
74.6±9.8 58.0±8.3 0.001 49.4±5.0 48.1±5.0 0.865 
Fasting 
FFA 
(mmol/l) 
0.85±0.08 0.77±0.05 0.207 0.72±0.09 0.80±0.07 0.263 
Fasting 
triacylglyce
rol (mmol/l) 
1.5 (0.6-
3.7) 
1.1 (0.5-
2.2) 
0.011 1.2±0.2 1.1±0.2 0.16 
Fasting 
ALT (U/l) 
37.7±4.1 25.7±2.4 0.009 24.3±2.8 22.1±3.7 0.542 
Fasting 
GGT (U/l) 
33 
(13-148) 
15 
(7-69) 
0.002 23 
(8-39) 
11 
(5-122) 
0.234 
 
Table 1. Anthropometric and metabolic data before and at 8 weeks post-operatively 
in the T2DM and NGT groups. * indicates a statistically significant difference 
between the 2 groups at baseline. #  indicates a statistically significant difference 
between the 2 groups at week 8. 
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Legend to Figures 
 
Figure 1. (A) Change in first phase insulin response (baseline to 6 min ISR shown as 
median and 25th-75th percentile)(pre-surgery difference between groups p=0.011; pre-
surgery  to week 8 change p=0.005 and  p=0.9 for T2DM and NGT respectively.(B) 
Pancreatic triacylglycerol content (shown as mean and SEM) in the T2DM and NGT 
groups pre-surgery (p<0.01) and then at 8 post-operative weeks (p<0.01 and p=0.44 
for pre-surgery to 8 week change for T2DM and NGT respectively). 
 
Figure 2.  Stepped insulin secretion test with arginine, showing (panels A) the 
induced change in plasma glucose pre-surgery  (open circles) and week 8 (closed 
circles), (panels B) pre-surgery insulin secretion rates (median and 25th-75th 
percentile), and (panels C) post-surgery insulin secretion rates (median and 25th-75th 
percentile) for the T2DM and NGT groups. 
 
Figure 3. Glucose (panels A), insulin (panels B), total GLP-1 (panels C) and total GIP 
(panels D) levels (mean ± SEM) during the 2 hour meal test in the T2DM and NGT 
groups pre-surgery (open circles)and week 8 (closed circles). Inset graph displays 
fasting (open bar) and 20 min (black bar) levels pre-surgery compared to week 8. The 
more rapid 0-20 min increase in post-surgery plasma glucose (p<0.001 and p<0.005), 
insulin (p<0.01 and p=0.03), GLP-1 (p<0.001 and p=0.002) and GIP (p=0.001 and 
p=0.016) was similar for T2DM and NGT respectively.  
 
 
